What Happened
An analysis of clinical notes drawn from more than 15 million medical records has documented a roughly 33-fold rise in newly confirmed BPC-157 users between early 2020 and early 2026, a period in which the peptide's human evidence base barely changed.
Researchers at the data analytics firm nference searched the records for mentions of the compound, then used large language models with physician review to separate documented use from passing references. Of 1,536 patients whose notes mentioned BPC-157, 1,039 had documented use. Newly confirmed users rose from 4 in the first quarter of 2020 to 134 in the first quarter of 2026. The findings were posted as a preprint on September 7 and have not been peer reviewed.
The user population also changed shape. The male share climbed from 57% to 70%, and mean age fell from 55 to 49. Among the 972 users with documented race, 96% were White.
Who Is Affected
Where a reason for use was recorded — 644 patients — pain led at 33%, followed by gastrointestinal conditions such as reflux, inflammatory bowel disease or gastritis at 14%, prior injury at 11%, and post-surgical healing at 10%.
Sourcing data are equally pointed. Of 205 users with a documented supply source, 36% obtained BPC-157 through a compounding pharmacy and 35% through a gray-market vendor. Just over half of all confirmed users also took at least one other agent, most often testosterone, nonsteroidal anti-inflammatory drugs, TB-500 — its partner in the so-called "Wolverine stack" — or corticosteroids.
Timeline
- First quarter 2020 — four newly confirmed users.
- First quarter 2026 — 134 newly confirmed users, roughly 33 times the 2020 figure.
- September 7, 2026 — preprint posted ahead of peer review.
- October 2026 — HHS issues an enforcement discretion policy covering BPC-157 compounding while FDA continues rulemaking.
What This Means for Researchers
Only 354 of the 1,039 confirmed users had a documented directional response, and 79% of that subset improved. That is not an efficacy signal. Flynn McGuire, MD, of the University of Utah, who was not involved in the analysis, noted that roughly half of documented users were also taking other drugs or undergoing interventions such as physical therapy or surgery, and that the study had no placebo or untreated comparison group, no standardized dose or formulation, and no consistent outcome measurement.
Discontinuation data point the same way. Where stopping was documented, clinician advice was the most common reason, followed by adverse events spanning neuropsychiatric, dermatologic and gastrointestinal symptoms. FDA's Adverse Event Reporting System has logged 10 serious reports tied to BPC-157 since 2021, eight of them in 2026 — reports that argue for follow-up rather than establish causation.
The study's contribution is epidemiological. It shows use spreading faster than the trial base, and it suggests most physicians are not systematically asking patients about peptides: study leader Venky Soundararajan, PhD, said the true scope of use is likely undercounted.
How to Verify Your Peptides
Reported outcomes mean little if a product's identity and purity are undocumented. Our explainers cover how testing works, identity, purity and fill-weight testing, and HPLC versus LC-MS analysis.
Safe Alternatives
The BPC-157 reference page sets out what is established and what is not, vendor records show which suppliers publish independent certificates of analysis, and the peptide index covers compounds with stronger human data behind them.
Sources
Industry reports on the preprint analysis of clinical notes (nference, September 2026); regulatory announcements on peptide compounding; FDA Adverse Event Reporting System summary data.